Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211367 · ClinicalTrials.gov registry record · Phase 2
Treatment of Radiation Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)
A Phase 2 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00211367 is a Phase 2 study that was terminated before completion, run by Manhattan Eye, Ear & Throat Hospital. The registered enrollment target is 2 participants.
The verdict
NCT00211367, a Phase 2 study, was terminated before completion, sponsored by Manhattan Eye, Ear & Throat Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Radiation retinopathy is a disease of the retina. It occurs in people who have received or been exposed to radiation near the eyes. The blood vessels are abnormal and may grow which lead to scarring and a loss of central vision. Currently, the treatment for radiation retinopathy is laser photocoagulation. This treatment has been found to have limited use in this type of condition. Compassionate use of anecortave acetate injection is being considered to prevent the growth of the blood vessels under the retina.
Interventions
- DRUG Anecortave Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2004-04 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00211367
The ClinicalTrials.gov registry entry for NCT00211367 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Manhattan Eye, Ear & Throat Hospital, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anecortave Acetate is the first listed.
NCT00211367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00211367 about?
NCT00211367 is a clinical study titled "Treatment of Radiation Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)". Radiation retinopathy is a disease of the retina. It occurs in people who have received or been exposed to radiation near the eyes. The blood vessels are abnormal and may grow which lead to scarring and a loss of central vision. Currently, the treatment for radiation retinopathy is laser photocoagul...
What is the current status of trial NCT00211367?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2004-04. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00211367?
The interventions under investigation include: Anecortave Acetate (DRUG).
Who is sponsoring clinical trial NCT00211367?
This trial is sponsored by Manhattan Eye, Ear & Throat Hospital, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.